MedTrace Logo

Itacitinib in Advanced Hepatocellular Carcinoma

NCT04358185 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-05-04

Study results available
· View outcomes & findings →

Summary

This research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer. Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body.

Conditions

Interventions

DRUG

Itacitinib

Novel and small molecule selective inhibitor of JAK1

Sponsors & Collaborators

  • Incyte Biosciences UK

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Rohini Sharma, Prof. · Professor Clinical Pharmacology and Medical Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-03
Primary Completion
2023-04-07
Completion
2023-04-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04358185 on ClinicalTrials.gov